Year-end Sale % OFF 
Abstract
Anxiety and depression are commonly comorbid with painful diabetic peripheral neuropathy (DPN). Data from 3 randomized, placebo-controlled, 8-13 week trials of pregabalin (300 or 600 mg/d) as treatment of painful DPN were pooled and retrospectively analyzed to investigate relationships between changes in pain and severity of anxiety and depression. Endpoint–LOCF mean pain score (MPS, scale of 0 [no pain] to 10 [worst possible pain]) was the primary efficacy measure, and the Hospital Anxiety and Depression Scale anxiety (HADS-A) and depression (HADS-D) subscales were secondary efficacy measures.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
